Residual solvent impurities in pharmaceuticals are trace amounts of volatile organic compounds used in drug production that remain in the final drug product. Strict regulations require close monitoring on the presence of residual solvent, as even trace amounts can impact drug safety and efficacy.
The acceptable level of residual solvents has been established by the ICH. USP has implemented a new test requirement for the control of residual solvents in drug products. With Agilent smart GC, consumable and supplies enable Accurate, Reproducible Results while Streamlining Your Residual Solvents Analysis Workflow.
You can now trust Agilent not only with latest technology and application support but also provide financial solutions to purchase this technology with easy payment plans.
With Agilent financial solutions we offer you:
- Customized Solution
- Flexible tenor
- Attractive financial offer
- Fixed and predictable cost
- After lease tenor – Easy – upgradation of asset
Download application notes on Analysis of USP Method <467> on GC 8890 and ICH Q3C (R5) consumable workflow ordering guide.
